Avanir Pharmaceuticals has entered into an exclusive, multi-year agreement with Merck their new pharma partners, known as MSD outside the United States and Canada, to co-promote Merck's type 2 diabetes therapies JANUVIA (sitagliptin) and the sitagliptin family of products in the long-term care institutional setting in the United States.
Avanir's institutional sales force will promote the sitagliptin family of products to health care practitioners in the long-term care institutional setting beginning in October 2013.
Under the terms of this agreement between the pharma partners, Avanir will be compensated via a fixed fee plus an incentive-based payment.
Merck will continue to remain responsible for the promotion of the sitagliptin family of products in all other settings and will remain responsible for all other aspects of research, manufacturing and marketing.
Report: Partnering Deals and Alliances with Merck & Co
Report: Diabetes Partnering
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity